EsoBiotec
About EsoBiotec
EsoBiotec is a company founded in 2020 by Jean-Pierre Latere was acquired by Astrazeneca in March 2025.. EsoBiotec has raised $2.15 million across 2 funding rounds from investors including Astrazeneca, Invivo Partners and UCB Ventures. The company has 8 employees as of December 31, 2022. EsoBiotec offers products and services including ENaBL Vector Platform and Off-the-Shelf Therapies. EsoBiotec operates in a competitive market with competitors including Moderna, BeiGene, Incyte, MorphoSys and Poseida Therapeutics, among others.
- Employees 8 as on 31 Dec, 2022
- Founders Jean-Pierre Latere
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Esobiotec
-
Annual Revenue
-
Net Profit
$-1.06 M (USD)-406as on Dec 31, 2022
-
EBITDA
$1.53 M (USD)898as on Dec 31, 2022
-
Total Equity Funding
$2.15 M (USD)
in 2 rounds
-
Latest Funding Round
$2.15 M (USD), Series A
Dec 11, 2023
-
Investors
Astrazeneca
& 5 more
-
Employee Count
8
as on Dec 31, 2022
-
Acquired by
Astrazeneca
(Mar 17, 2025)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of EsoBiotec
EsoBiotec offers a comprehensive portfolio of products and services, including ENaBL Vector Platform and Off-the-Shelf Therapies. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Enables in vivo cell therapies for cancer treatment and disease management.
Provides immune-shielded treatments for solid tumors and autoimmune conditions.
Funding Insights of EsoBiotec
EsoBiotec has successfully raised a total of $2.15M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $2.15 million completed in December 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 2
- Last Round Series A — $2.2M
- First Round First Round
- Investors Count 5
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec, 2023 | Amount | Series A - EsoBiotec | Valuation | Invivo Partners |
|
| Jun, 2021 | Amount | Seed - EsoBiotec | Valuation | UCB Ventures , Thuja Capital |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in EsoBiotec
EsoBiotec has secured backing from 6 investors, including venture fund and institutional investors. Prominent investors backing the company include Astrazeneca, Invivo Partners and UCB Ventures. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Invivo Partners is engaged in venture capital investments for early-stage healthcare companies.
|
Founded Year | Domain | Location | |
|
UCB Ventures is focused on strategic corporate venture investments.
|
Founded Year | Domain | Location | |
|
Early-stage centric life sciences focused VC firm funding in Netherlands, Belgium and the US
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by EsoBiotec
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - EsoBiotec
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Esobiotec Comparisons
Competitors of EsoBiotec
EsoBiotec operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, BeiGene, Incyte, MorphoSys and Poseida Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| domain | founded_year | HQ Location |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Small molecules are developed for cancer and skin disease treatments.
|
|
| domain | founded_year | HQ Location |
Therapeutic antibodies for cancer and other diseases are developed.
|
|
| domain | founded_year | HQ Location |
Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies
|
|
| domain | founded_year | HQ Location |
Developer of antibodies to treat complement-mediated neurodegenerative diseases
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Esobiotec
Frequently Asked Questions about EsoBiotec
When was EsoBiotec founded?
EsoBiotec was founded in 2020 and raised its 1st funding round 1 year after it was founded.
Who is the current CEO of EsoBiotec?
Jean-Pierre Latere is the current CEO of EsoBiotec. They have also founded this company.
Is EsoBiotec a funded company?
EsoBiotec is a funded company, having raised a total of $2.15M across 2 funding rounds to date.
How many employees does EsoBiotec have?
As of Dec 31, 2022, the latest employee count at EsoBiotec is 8.
What does EsoBiotec do?
EsoBiotec was founded in 2020 within the biotechnology sector, where in vivo adoptive cell therapies for cancer and autoimmune diseases are developed. Immune cells are engineered directly in patients to avoid ex vivo manufacturing complexities. A proprietary vector platform is employed for single-injection, off-the-shelf treatments that minimize rejection risks and enable scalable, high-yield production. Operations focus on simplifying logistics and improving accessibility through reduced costs.
Who are the top competitors of EsoBiotec?
EsoBiotec's top competitors include Moderna, BeiGene and Juno Therapeutics.
What products or services does EsoBiotec offer?
EsoBiotec offers ENaBL Vector Platform and Off-the-Shelf Therapies.
Who are EsoBiotec's investors?
EsoBiotec has 6 investors. Key investors include Astrazeneca, Invivo Partners, UCB Ventures, Thuja Capital, and Sambrinvest.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.